Atossa Therapeutics Presents Clinical Trial Updates on (Z)-Endoxifen at SABCS 2025

Atossa Therapeutics presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium. Studies highlight the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reduction. The company's Phase 2 EVANGELINE study is expected to continue enrollment and data generation for neoadjuvant ER+/HER2- breast cancer. Atossa is also committed to advancing a low-dose treatment strategy to reduce mammographic breast density, which has been associated with a higher risk of developing future breast cancer.